Advertisement
Australia markets open in 4 hours 12 minutes
  • ALL ORDS

    8,020.90
    +25.20 (+0.32%)
     
  • AUD/USD

    0.6691
    +0.0063 (+0.96%)
     
  • ASX 200

    7,753.70
    +26.90 (+0.35%)
     
  • OIL

    78.85
    +0.83 (+1.06%)
     
  • GOLD

    2,391.10
    +31.20 (+1.32%)
     
  • Bitcoin AUD

    99,339.62
    +7,231.68 (+7.85%)
     
  • CMC Crypto 200

    1,389.55
    +121.60 (+9.59%)
     

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc

DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024.

To access the conference call, investors are invited to dial +1 (800) 715-9871 (U.S. and Canada) or +1 (646) 307-1963 (International) and use the conference ID 2270373. A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Mogerley
Stern Investor Relations, Inc.
Courtney.Mogerley@sternir.com
(212) 698-8687

Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162